Showing 361 - 380 results of 2,913 for search '"The Real World"', query time: 0.14s Refine Results
  1. 361
  2. 362

    Do continuous glucose monitoring (CGM) metrics predict macrovascular and microvascular complications in diabetes? The FACULTY protocol of a retrospective real-world cohort study by Eric Vicaut, Ramzi A Ajjan, J Seufert, Gérard de Pouvourville, Emmanuel Cosson, Laure Carcaillon-Bentata, Tadej Battelino, Patrick Blin, Fleur Levrat-Guillen, Michael Joubert

    Published 2025-01-01
    “…Here, we present the protocol for a real-world cohort study, aiming to establish the relationship between CGM-derived glycaemic metrics and the incidence of macrovascular and/or microvascular complications in people with diabetes.Methods and analysis This cohort study will use data from all CGM new users (FreeStyle Libre system) in France who uploaded their glycaemic values onto the LibreView cloud-based system, linked with data from the French nationwide Système National des Données de Santé claims database. …”
    Get full text
    Article
  3. 363
  4. 364

    Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France by Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P. Nagar, Mohamad Mohty

    Published 2019-01-01
    “…Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk. …”
    Get full text
    Article
  5. 365
  6. 366

    Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

    Published 2024-01-01
    “…Methods: We report real-world data on six consecutive patients with HER2-mutant NSCLC who received zongertinib through a named patient use program between December 2023 and June 2024. …”
    Get full text
    Article
  7. 367

    Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer by Jing Zhang, Wenjie Li

    Published 2025-02-01
    “…Abstract Background While clinical trials have demonstrated enduring responses to amivantamab among advanced non-small cell lung cancer (NSCLC) patients bearing EGFR exon 20 insertion mutations, the associated toxicity profile in real-world scenarios remains elusive. Methods This pharmacovigilance study analyzed data from the FDA Adverse Event Reporting System (FAERS) to investigate adverse events associated with amivantamab over the period from September 2021 to December 2023. …”
    Get full text
    Article
  8. 368

    Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy by George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett, William Drake

    Published 2018-01-01
    “…**Objectives:** This study describes real-world clinical practice and treatment patterns with PDE-5i monotherapy including events indicative of clinical worsening, treatment modifications, adherence, allcause healthcare resource utilization, and costs. …”
    Get full text
    Article
  9. 369

    Clinical Outcomes from Unselected “Real-World” Patients with Long Coronary Lesion Receiving 40 mm Biodegradable Polymer Coated Sirolimus-Eluting Stent by Anurag Polavarapu, Raghava Sarma Polavarapu, Jayesh Prajapati, Kamlesh Thakkar, Asif Raheem, Tamanpreet Mayall, Ashok Thakkar

    Published 2015-01-01
    “…We aimed to examine the safety and efficacy of the long (40 mm) biodegradable polymer coated Indolimus sirolimus-eluting stent (SES) in real-world patients with long coronary lesions. Methods. …”
    Get full text
    Article
  10. 370
  11. 371
  12. 372
  13. 373
  14. 374
  15. 375
  16. 376
  17. 377
  18. 378
  19. 379
  20. 380